

05 Oct 2020 |

# Quick Listen: Scrip's Five Must-Know Things

*Weekly Audio Catch-Up*

by **Ian Haydock**

Join us for an audio roundup of major events in the international biopharma industry over the past week, as reported by Scrip's global team.

Take a brief audio tour around Scrip's Five Must-Know Things, this time covering major developments in the business week ended 2 October 2020.

In this edition, the industry pushes back on claims it could move even faster on coronavirus vaccines, promising results are reported for a COVID-19 antibody cocktail, US House hearings on pricing get off to a slow start, top-level executive changes are announced, and a progress update on a major acquisition.

This and other Informa Pharma Intelligence podcasts are also now voice-accessible as a skill on Alexa smart speakers and the Alexa app, under the "Business and Finance" category. Just say "Alexa, Open Informa - Pharma Intelligence" and then ask for a specific podcast or topic.

Stories mentioned in this episode:

(Also see "[Moderna CEO Bancel Pushes Back On Trump Debate Comments On COVID-19 Vaccine](#)" - Scrip, 30 Sep, 2020.)

(Also see "[Regeneron's COVID-19 Antibody Cocktail Shows Early Promise, But Does It Merit An EUA?](#)" - Scrip, 30 Sep, 2020.)

(Also see "[US House Drug Pricing Hearings Start Slow As Pharma Execs Dodge Some Punches](#)" - Scrip, 30 Sep, 2020.)

(Also see "[\*Changing Of The Guard At Merck KGaA With Garijo Succeeding Oschmann As CEO\*](#)" - Scrip, 29 Sep, 2020.)

(Also see "[\*Nearly One Year Post-Celgene: BMS CMO On Pipeline Progress, Clinical Trial Diversity\*](#)" - Scrip, 24 Sep, 2020.)

[Click here to explore this interactive content online](#) 